A randomised study to optimise clinical outcomes in patients with FLT3 mutant AML

Wei, Andrew (Primary Chief Investigator (PCI))
Bradstock, Kenneth (Chief Investigator (CI))
Levis, Mark (Chief Investigator (CI))
Murray, Michael (Chief Investigator (CI))
Roberts, Andrew W. (Chief Investigator (CI))

Project: Research

Status	Finished
Effective start/end date	1/01/13 → 31/12/17

Funding

NHMRC - National Health and Medical Research Council (Australia): A$1,111,891.00

1 Article

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
Loo, S., Roberts, A. W., Anstee, N. S., Kennedy, G. A., He, S., Schwarer, A. P., Enjeti, A. K., D'Rozario, J., Marlton, P., Bilmon, I. A., Taper, J., Cull, G., Tiley, C., Verner, E., Hahn, U., Hiwase, D. K., Iland, H. J., Murphy, N., Ramanathan, S. & Reynolds, J. & 17 others, Ong, D. M., Tiong, I. S., Wall, M., Murray, M., Rawling, T., Leadbetter, J., Rowley, L., Latimer, M., Yuen, S., Ting, S. B., Fong, C. Y., Morris, K., Bajel, A., Seymour, J. F., Levis, M. J., Wei, A. H. & on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG), 7 Dec 2023, In: Blood. 142, 23, p. 1960-1971 12 p.
Research output: Contribution to journal › Article › Research › peer-review

Open Access

31 Link opens in a new tab Citations (Scopus)